Research programme: respiratory disorders therapeutics - AstraZeneca

Drug Profile

Research programme: respiratory disorders therapeutics - AstraZeneca

Alternative Names: OX-CLI

Latest Information Update: 02 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orexo
  • Developer AstraZeneca
  • Class Antiasthmatics
  • Mechanism of Action Leukotriene-C4 synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Respiration disorders

Most Recent Events

  • 31 Dec 2017 Discontinued - Preclinical for Respiration disorders in European Union (PO)
  • 09 May 2017 Drug candidates are still in preclinical trials for Respiration disorders in European Union
  • 17 Mar 2016 AstraZeneca exercises option to acquire OX-CLI research programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top